Inspire Investing LLC Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Inspire Investing LLC purchased a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 341,223 shares of the biopharmaceutical company’s stock, valued at approximately $758,000. Inspire Investing LLC owned approximately 0.18% of Esperion Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after buying an additional 3,688,796 shares in the last quarter. Armistice Capital LLC purchased a new stake in Esperion Therapeutics in the 4th quarter worth $9,568,000. Jump Financial LLC purchased a new stake in Esperion Therapeutics in the 4th quarter worth $77,000. Bellevue Group AG increased its stake in Esperion Therapeutics by 136.5% in the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after buying an additional 5,739,800 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Esperion Therapeutics during the first quarter valued at about $69,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Trading Down 4.0 %

Shares of NASDAQ:ESPR opened at $1.68 on Friday. Esperion Therapeutics, Inc. has a 12 month low of $0.70 and a 12 month high of $3.40. The company has a 50-day moving average price of $1.99 and a 200 day moving average price of $2.23. The company has a market cap of $318.29 million, a price-to-earnings ratio of -1.70 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million during the quarter, compared to the consensus estimate of $51.90 million. As a group, equities analysts forecast that Esperion Therapeutics, Inc. will post -0.04 EPS for the current year.

Wall Street Analyst Weigh In

ESPR has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Monday, August 12th. Bank of America lowered Esperion Therapeutics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $2.90 to $2.50 in a research report on Thursday, June 20th. Needham & Company LLC cut their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Finally, StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.